Combining gilteritinib with the anti‐CD33 antibody gemtuzumab plus cytarabine for FLT3‐ITD‐mutated relapsed/refractory AML is in the phase II stage (NCT05199051). This evidence concerns the gene FLT3 and acute myeloid leukemia.